From WisPolitics.com/WisBusiness.com …
— Archeus Technologies in Madison and WARF are launching a clinical trial this year for a targeting molecule used in treating prostate cancer.
The organizations yesterday announced the plans to further develop ART-101, a receptor-based targeting molecule developed at UW-Madison’s Advanced Radiotheranostics lab. It’s designed to deliver radioactive isotopes within the body as part of a targeted treatment approach.
ART-101 has been tested in preclinical studies that found it demonstrated “significantly higher tumor uptake and retention” than an existing prostate cancer treatment, according to the announcement. Phase 1 of the clinical trial process will begin this year.
Evan Sengbusch, CEO of Archeus Technologies, is touting the company’s close ties to the university and expertise in bringing new drugs to market. He notes the targeting molecule is part of its portfolio of therapies for cancers that are “particularly challenging” to treat.
“With strong preclinical data supporting the continued development of ART-101, Archeus is eager to lead the evaluation of this novel candidate through first-in-human studies,” he said in a statement.
The molecule was created with support from the WARF Accelerator program, which helps inventors advance commercially viable technologies and other breakthroughs.
Jeanine Burmania, senior director of intellectual property and licensing at the Wisconsin Alumni Research Foundation, notes ART-101 has “significant potential” to advance the field of theranostics. This approach involves diagnostics and therapeutics, typically using radioactive drugs, to find and treat cancer.
“Encouraging preclinical data suggest that ART-101 could help increase lifespan and be more effective in treating prostate cancer than current therapies,” Burmania said in a statement.
See the release below and listen to an earlier podcast with Laura Strong, a strategic advisor for Archeus Technologies.
— Exact Sciences plans to introduce an updated version of its Oncodetect test next year, improving its ability to identify circulating cancer DNA.
The Madison diagnostics business yesterday announced the “next-generation” version of its molecular residual disease is currently being tested across multiple types of solid tumors. It will be able to track up to 5,000 patient-specific cancer variants, the release notes, boasting an “ultra low” detection threshold.
The updated version of Oncodetect is based in part on a genetic sequencing technology called MAESTRO, created in collaboration with the Broad Institute in Cambridge. Exact Sciences has exclusive rights to the technology, which can detect certain circulating tumor DNA mutations “with high accuracy” while keeping related costs low, the company says.
Brian Baranick, executive vice president and general manager of precision oncology for Exact Sciences, says the next version of Oncodetect will “enhance sensitivity and expand clinical utility” thanks to the sequencing technology.
“We launched the Oncodetect test to give clinicians and patients a powerful tool for detecting cancer recurrence earlier and with greater precision — progress that’s already being realized,” Baranick said in a statement.
Meanwhile, the company yesterday also rolled out clinical validation study findings that will be presented at the 2025 American Society of Clinical Oncology Annual Meeting, which begins tomorrow in Chicago. Results from the Beta-CORRECT study show the test “significantly improves prognosis prediction” compared to current standard of care, the release shows.
See more in the release below.
Top Stories
– HHS cancels funding for Moderna vaccines to fight pandemic flu
– U.S. Cancels Contract With Moderna to Develop Bird Flu Vaccine
– Feds Chop Enforcement Staff and Halt Rules Meant To Curb Black Lung in Coal Miners
– Will you be able to get a COVID-19 shot? Here’s what we know so far
– Study reveals decline in mental health among US mothers
– US cancels more than $700 million funding for Moderna bird flu vaccine
Press Releases
